期刊文献+

使用不同时间头孢哌酮对大鼠肠道真菌增殖和易位的影响 被引量:1

下载PDF
导出
摘要 目的:观察连续使用不同时间头孢哌酮钠舒巴坦钠后大鼠肠道真菌增殖的变化与肠道真菌易位的关系。方法:50只大鼠按观察时间0、3、6、9、12天随机分为5组,即A、B、C、D和E组,A组为使用前对照组,各组用相同剂量的头孢哌酮舒巴坦钠,于相应时间内取肠内容物、肠系膜、胰腺、肺组织及血作真菌培养,检测血浆1-3-β-D葡聚糖(1-3-G)水平。结果:用药3天后开始出现肠道真菌增殖,6天肠道真菌增殖明显,用药9天后开始出现肠道真菌易位。1-3-G水平与肠道真菌增殖及易位呈正相关关系。结论:连续长时间使用头孢哌酮钠舒巴坦钠使肠道真菌明显增殖,并与肠外真菌易位有关,使用头孢哌酮钠6~9天后预防使用抗真菌药物是合适的。
机构地区 贵州省人民医院
出处 《贵阳中医学院学报》 2011年第3期122-125,共4页 Journal of Guiyang University of Chinese Medicine
  • 相关文献

参考文献11

  • 1蒋东,马虹.真菌感染的现状和抗真菌药物的研究进展[J].海峡药学,2008,20(9):105-107. 被引量:8
  • 2Harvey RL, Myers JP. Nosocomial fungemia in a large communi- ty teaching hospital. Arch Med. 1987. 147:2117 -2120.
  • 3Klein JJ. Watanakunakorn C. Hospital - acquired fungemia: its natu- ral course and clinical significance. Am J Med. 1979.67 : 51 -58.
  • 4Fraser J, Jones M, Dunkel J,cte. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. In : Rex JH, Meunier F, eds. Serious Candida Infections: Risk Factors, Treatment, and Prevention. Selected Readings: Focus on Fluconazole. New York : Pfizer Inc; 1995 : 107 - 119.
  • 5刘宗师,陈裕胜,吴晓琴.危重症患者并发深部真菌感染的早期治疗[J].广州医药,2007,38(4):19-21. 被引量:3
  • 6Dean D, Burchard KW. Fungal infection in surgical patients [M]. AmJ Surg. 1996,171:374-382.
  • 7伍民生,赵晓琴,施焕中,陈强.院内肺部真菌感染的危险因素分析[J].临床荟萃,2007,22(9):644-645. 被引量:4
  • 8赵立新,乔翠华.使用抗生素所致肠道真菌感染的临床分析[J].中国厂矿医学,2008,21(3):290-290. 被引量:3
  • 9Verweij PE, Figueroa J, van Burik J, et al. Clinical applications of non - culture based methods for the diagnosis and management of opportunistic and endemic mycoses [J]. Med mycol, 2000,38 (suppl 1) :161 -171.
  • 10Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of in- vasive aspergillosis [ J ]. Lancet infect Dis, 2005,5 (10) : 609 - 622.

二级参考文献32

  • 1侯芳,肖永红.新型抗真菌药物研究与临床应用[J].临床药物治疗杂志,2005,3(5):8-13. 被引量:6
  • 2郑洁,胡国信,龚菊梅.支气管哮喘患者医院肺部真菌感染的临床分析[J].中华医院感染学杂志,2005,15(9):999-1000. 被引量:12
  • 3范润玉,吴瑶.医院内深部真菌感染166例分析[J].中华医院感染学杂志,1996,6(3):138-140. 被引量:164
  • 4陈灏珠.实用内科学[M](第10版)[M].北京:人民卫生出版社,1998.2076-2077.
  • 5Shelton BK. Opportunistic fungal infections in the critically ill [K]. Crit Care Nurs Clin North Am,2000,12(3) :323-340.
  • 6McKinnon PS, Goff DA, Kern JW, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit[J]. Arch Surg, 2001, i36(12) : 1401-1408.
  • 7Flanagan PG,Barnes RA. Fungal infection in the intensive care unit[J]. J Hosp Infect, 1998,38(3) :163-177.
  • 8Resende JC, de Resende MA, Saliba JL. Prevalence of Candida spp in hospitalized patients and their risk factors[J]. Mycoses, 2002,45(8) :306-312.
  • 9Patricia Munoz.Criteria used when initiating antifungal the-rapy against Candida spp.in the intensive care unit[J].International Journal of Antimicrobial Agent,2000,15:83-90.
  • 10Thom JG.A retrospective study to evaluate a computer based model for amplifying 1(early antifungal intervention and 2) microbial detection of patients at risk for fingemia[abstract].Presented at Seventh Annual Focus on Fungal infections San Antonio,TX11997,3,13-15.

共引文献13

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部